MedTrace Logo

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

NCT02922777 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-02-21

No results posted yet for this study

Summary

This study is being done to evaluate the safety of the investigational study drug, BGB324 when administered in combination with docetaxel, and to establish the maximum tolerated dose.

Conditions

  • Non-Small Cell Lung Carcinoma

Interventions

DRUG

BGB324

75 mg/m2 every 21 days

DRUG

Docetaxel

75 mg/m2 given IV every 21 days

Sponsors & Collaborators

  • Texas Tech University Health Sciences Center

    collaborator OTHER

  • BerGenBio ASA

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • David E Gerber, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2023-02-06
Completion
2023-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922777 on ClinicalTrials.gov